SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss the potential impact of critical mineral deals and the CEO's visit to Washington D.C., possibly related to government support. Community members are debating the stock's future, focusing on upcoming catalysts and the potential for a significant rally within the critical metals sector. Some are pointing to Tesla's plans to reduce reliance on Chinese components as a tailwind for TMC.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as investors react to news of an $8.2M contract and the closing of the Sentrycs acquisition, with discussions focusing on the potential impact of a shareholder vote and possible dilution. The community is debating the company's growth prospects, comparing it to other drone and tech companies, and analyzing its position in the counter-UAS market. Some traders express concern over dilution and recent price action while others remain optimistic about the long-term potential of ONDS in the defense and security sectors.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending ahead of its earnings release, with community members debating whether the results will justify current valuations and concerns of an AI bubble. Discussions range from potential price movements to the impact of Saudi Arabian investments in AI and advanced chip sales. Sentiment is mixed, with some anticipating a positive market catalyst and others bracing for a sell-off, with some calling for it to reach 220+.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Olema Pharmaceuticals is trending due to positive data from a Roche breast cancer trial, sparking optimism for Olema's own treatment and a potential buyout. The community is actively debating whether to go long or short, with some anticipating a short squeeze while others foresee an offering. Discussions also involve analyst price target upgrades and potential parallels to other biotech stocks with similar price action.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending as investors discuss the company's GPU-accelerated QLEO with NVIDIA CUDA-Q compatibility, which some believe will significantly accelerate quantum algorithm simulation. Community members are speculating about potential partnerships and future growth in the quantum computing sector, viewing this development as a major step forward. Some are focused on the company's positioning within the quantum-safe solutions sector for stablecoins and digital assets.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing volatile price action as traders digest conflicting signals and await key events, including Nvidia's earnings and the potential release of Epstein files. Community sentiment is mixed, with some anticipating a Santa rally while others brace for a deeper correction, sparking active debate around market direction and potential manipulation.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending despite mixed earnings, as the company reaffirmed its full-year outlook, sparking debate about the resilience of the home improvement sector. Community discussions revolve around the impact of housing market trends, potential Fed rate cuts, and the company's strategic acquisitions on future performance. Some traders are betting on a near-term rise, while others remain cautious due to concerns about consumer spending and economic uncertainty.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending amidst discussions about its low valuation and high short interest, with some seeing a potential buying opportunity or short squeeze. However, negative sentiment persists due to concerns about cash burn, leadership, and recent price declines, as well as comparisons to competitors like Tesla. Partnerships with Uber and NVIDIA are also being discussed, but overall sentiment remains mixed as the stock continues to trade near all-time lows.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

COST is seeing mixed sentiment as the stock consolidates, with some traders pointing to potential downside based on technical patterns and valuation concerns, while others highlight the company's strong membership model and recent sales data. Community members are actively discussing potential price movements, options strategies, and the impact of broader economic factors on the stock's performance. Option traders are closely watching for breakout patterns and actionable signals.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid reports of a potential bidding war, with Paramount Skydance, Comcast, and Netflix reportedly preparing offers; community chatter suggests speculation around deal price and potential outcomes. Shareholders are closely watching for developments as the November 20th bid deadline approaches, with some analysts predicting bids reaching $30 or higher.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Olema’s lead product candidate, Palazestrant, belongs to the same class of drugs as Roche’s and is being studied in breast cancer.&nbsp;</li><li>Oppenheimer raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.&nbsp;</li><li>The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.</li></ul>Shares of Olema Pharmaceuticals Inc. (OLMA) more than doubled Tuesday morning on the heels of Roche announcing positive results from its late-stage trial in breast cancer.Roche was <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.roche.com/media/releases/med-cor-2025-11-18">evaluating</a> Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. In the study, Giredestrant treatment showed a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard-of-care endocrine therapy.Giredestrant is an investigational, oral, selective oestrogen receptor degrader or SERD. According to Roche, this is the first late-stage study of a SERD to demonstrate a significant benefit in the adjuvant setting.<h2 class="st-heading-2">Expert Take</h2>As per Oppenheimer, Olema shares were trading pre-market on news that Roche's (RHHBY) trial met its primary endpoint. The analyst subsequently raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.Oppenheimer said it was not expecting this readout, as the entire narrative has been around Roche's different breast cancer clinical trials. Nonetheless, the data are a welcome surprise, it added.Early breast cancer is a multi-billion-dollar market, and one that the firm did not have in its model. These data also incrementally derisk another Roche drug trial, which is testing oral SERDS against aromatase inhibitors in the frontline metastatic setting, Oppenheimer added.Olema’s lead product candidate, Palazestrant, is also a SERD being investigated in patients with recurrent, locally advanced, or metastatic forms of breast cancer. It is being evaluated as a single agent in a late-stage trial and in combination with ribociclib in another late-stage trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OLMA">OLMA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/59;" src="data:image/png;base64,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" width="622" height="59" alt="OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits"><figcaption>OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed pessimism about the stock, noting that the hype had passed by pre-market hours, when the stock was up over 200%.<stembedurl>https://stocktwits.com/ChannelRed/message/636586904</stembedurl>Another user, however, believes the stock will touch $100.<stembedurl>https://stocktwits.com/murphylaw/message/636586451</stembedurl>OLMA stock is up by 233% this year and by 125% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-shifts-to-royalty-driven-model-approves-125-m-buyback-plan/cLPVdKtRE7F">Zymeworks Shifts To Royalty-Driven Model From Licensed Drugs, Approves $125M Buyback Plan</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

Equity

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.


Olema Pharmaceuticals, Inc. $OLMA Holdings Raised by Persistent Asset Partners Ltd

Persistent Asset Partners Ltd increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 153.8% during the 2nd quarter, according to its most recent disclosure...

Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6.3% - Time to Buy?

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Here's Why...

Analysts Set Expectations for OLMA FY2025 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Research analysts at HC Wainwright issued their FY2025 EPS estimates for shares of Olema Pharmaceuticals in a report released on Tuesday...

FY2025 Earnings Estimate for OLMA Issued By Lifesci Capital

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at Lifesci Capital reduced their FY2025 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to...

Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 7.2% After Earnings Miss

Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 7.2% After Earnings Miss...

Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.05 EPS

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) released its earnings results on Monday. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05...

OLMA Stock Soars 47% in September So Far on Second PFE Deal

Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.

Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent...

$KLAR

$OLMA

$NBIS

$GRRR

Which of these trending stocks are you most bullish on for the next 5 years?

Current Price	$20.12
Prev Close	$8.52
Open	$26.46
Dividend Yield	0.00%
50-Day Moving Average	$8.93
Beta	1.10
Avg. Volume	1.44M
PE Ratio	-4.70

52-Week High	$11.54
52-Week Low	$2.86
Market Capitalization	$584.98M
EPS (Annual)	-$2.20
Price to Book	1.90
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

OLMA
Olema Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OLMA News

OLMAOlema Pharmaceuticals Inc